CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial re ...

Investors in Sotera Health Company (SHC) need to pay close attention to the stock based on moves in the options market lately. That is because the May 16, 2025 $10.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could ...

We add real-time buy and sell signals on these, as well as other trading opportunities which we provide in our active chat community. We look at companies with a defensible competitive advantage and the opportunity and/or business models which have the potential to generate considerable operational leverage.If you are interested in similarly small, high-growth potential stocks you could join us at our marketplace service SHU Growth Portfolio , where we maintain a portfolio and a watchlist of similar stocks. ...

Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product applicationSALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sit ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39729 SOTERA HEALTH COMPANY (Exact name of registrant as specified in its charter) Delaware 47-3531161 (State or other jurisdiction of incorporation ...

Safeguarding Global Health® Fourth-Quarter & Full-Year 2024 Earnings Results February 27, 2025 © 2025 Sotera Health Company | All Rights Reserved. Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this document refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This release contai ...

Financial Data and Key Metrics Changes - For the full year 2024, the company reported total revenue of $1.1 billion, marking a 4.9% increase compared to 2023, or 5.4% on a constant currency basis [7][27] - Adjusted EBITDA for 2024 grew by 3.9% to $548.6 million, resulting in an adjusted EBITDA margin of approximately 50% [27][28] - In Q4 2024, total revenue declined by 6.5% to $290 million, with adjusted EBITDA declining by 8.3% to $153 million [13][20] Business Line Data and Key Metrics Changes - Sterigenics reported a revenue growth of 4.2% to $179 million in Q4 2024, driven by favorable pricing and volume mix [22] - Nordion's revenue decreased by 29% to $57 million in Q4 2024, primarily due to unfavorable volume mix [24] - Nelson Labs experienced a revenue decline of 7.3% to $54 million in Q4 2024, attributed to unfavorable volume mix and higher employee compensation costs [25] Market Data and Key Metrics Changes - The company expects total revenue growth for 2025 to be in the range of 4% to 6% on a constant currency basis, with adjusted EBITDA growth projected at 4.5% to 6.5% [18][31] - The first quarter of 2025 is anticipated to be the lightest quarter, with gradual improvement expected throughout the year [32] Company Strategy and Development Direction - The company aims to focus on customer satisfaction, operational excellence, and disciplined capital deployment [9][38] - Strategic priorities include serving customers with end-to-end solutions and winning in growth markets [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in gradual volume recovery in 2025, despite some challenges in the first quarter [42] - The company is monitoring potential tariff impacts but has not incorporated them into guidance yet [31][76] Other Important Information - The company completed a capacity expansion in its Sterigenics business and made significant progress on EO facility enhancements [10][30] - The net leverage ratio improved slightly, finishing the year at 3.7 times [30] Q&A Session Summary Question: Overall volume backdrop and guidance for the year - Management indicated that 2024 played out as expected with gradual improvement, and they anticipate continued volume improvement in 2025 [42] Question: Margins and pricing assumptions - Management expects solid margin improvement throughout 2025, with Q1 typically being the lowest quarter [45] Question: Nelson Labs margin improvement - Management highlighted improvements in labor productivity and consolidation of a lab as key factors for margin enhancement in Nelson Labs [51][63] Question: Capacity concerns in Nelson Labs - Management confirmed that they are in a good position regarding capacity and have consolidated a lab to improve operating leverage [63] Question: Cross-selling initiatives between Sterigenics and Nelson Labs - Management reported positive progress in cross-selling initiatives, which are included in the 2025 guidance [72] Question: Tariff risks and cobalt supply - Management noted that cobalt has historically been exempt from tariffs and expressed confidence in managing potential impacts [110] Question: Disconnect in growth compared to competitors - Management acknowledged that while there may be quarterly discrepancies, they feel confident about their competitive position and execution [115]

Core Insights - Sotera Health Company reported revenue of $290.2 million for the quarter ended December 2024, a decrease of 6.5% compared to the same period last year [1] - The earnings per share (EPS) for the quarter was $0.21, down from $0.26 in the year-ago quarter, aligning with the consensus EPS estimate [1] - The reported revenue fell short of the Zacks Consensus Estimate of $291.56 million, resulting in a surprise of -0.46% [1] Financial Performance - Net Revenues for Sterigenics were reported at $179.43 million, slightly below the estimated $182.82 million, but showed a year-over-year increase of 4.2% [4] - Nelson Labs reported Net Revenues of $53.98 million, which was lower than the estimated $55.49 million, reflecting a year-over-year decline of 7.3% [4] - Nordion's Net Revenues were $56.79 million, exceeding the average estimate of $53.25 million, but represented a significant year-over-year decrease of 28.9% [4] Segment Income - Segment Income for Sterigenics was $99.59 million, slightly below the average estimate of $101.07 million [4] - Nelson Labs achieved Segment Income of $18.07 million, which was above the average estimate of $17.87 million [4] - Nordion's Segment Income was reported at $35.28 million, surpassing the average estimate of $33.55 million [4] Stock Performance - Shares of Sotera Health have returned -0.3% over the past month, compared to a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Sotera Health Company (SHC) reported quarterly earnings of $0.21 per share, matching the Zacks Consensus Estimate, but down from $0.26 per share a year ago [1] - The company posted revenues of $290.2 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.46% and down from $310.24 million year-over-year [2] - The stock has underperformed the market, losing about 0.3% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.14 on revenues of $262.37 million, and for the current fiscal year, it is $0.78 on revenues of $1.15 billion [7] - The estimate revisions trend for Sotera Health is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical Services industry, to which Sotera Health belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Revenue Results - Sotera Health Company announced preliminary revenue results for full-year 2024, which are within the guidance provided during the third quarter earnings release[6] - The revenue results are subject to completion of year-end financial closing procedures and audit by the independent registered public accounting firm[7] Business Update - Michael B. Petras, Jr., Chairman and CEO, will deliver a business update at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025[8]